Adagene(US:ADAG) Jin Rong Jie·2025-08-06 13:46Core Viewpoint - Tianyan Pharmaceuticals (ADAG) experienced a significant stock price increase of 10.05%, reaching $2.09 per share, with a total market capitalization of $98.45 million as of August 6 [1]. Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, reflecting a year-over-year decrease of 99.43% [1]. - The company's net profit attributable to shareholders was -$33.42 million, representing a year-over-year decline of 76.41% [1]. Company Overview - Tianyan Pharmaceuticals is a biopharmaceutical company listed on NASDAQ under the ticker ADAG, focused on the development of clinical products driven by its proprietary platform [1]. - The company aims to discover and develop novel cancer immunotherapies based on original antibodies, utilizing a powerful platform that combines computational biology and artificial intelligence [1]. - The company's antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, with the goal of creating globally innovative or best-in-class products [1].